serine/threonine kinase 36Genealiases: CILD46 · FU
Q-omics provides the consensus-scored STK36 profile across patient tissues and cancer cell-line models. STK36 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STK36 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, STK36 RNA expression shows 21,203 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where STK36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK36 survival associations across molecular data types. STK36 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK36 RNA expression–survival associations across cancer types. High STK36 expression shows unfavorable associations in ACC, UVM, LIHC, LGG and KIRC, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STK36 RNA expression.
This table summarizes STK36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STK36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK36 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, UCEC, CHOL and STAD. The COAD box plot shows higher STK36 RNA expression in tumor versus normal tissue (log2 FC = +0.992, t-test p < 0.001).
This table shows molecular features associated with STK36 in patient tissues and cancer cell lines. In patient samples, STK36 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, STK36 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
